Regulatory News:
Pursuant to the liquidity contract entrusted to TSAF Tradition Securities by IMPLANET (Euronext: ALIMP, FR0010458729, PEA-PME eligible) (Paris:ALIMP) (OTCQX:IMPZY), on 31 December 2018, the following assets appeared on the liquidity account:
- Number of shares: 170,500
- Cash balance of the liquidity account: €31,780.10
As a reminder, at the time of the last half-yearly report on 30 June 2018, the following resources were booked to the liquidity account:
- Number of shares: 160,000
- Cash balance of the liquidity account: €34,349.25
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 46 staff and recorded 2017 sales of €7.8 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Euronext Growth market in Paris. The Company would like to remind that the table for monitoring the BEOCABSA, OCA, BSA and the number of shares outstanding, is available on its website: http://www.implanet-invest.com/suivi-des-actions-80
View source version on businesswire.com: https://www.businesswire.com/news/home/20190115005785/en/
Contacts:
IMPLANET
Ludovic Lastennet
CEO
Tel.: +33 (0)5 57 99 55 55
investors@implanet.com
NewCap
Investor Relations
Julie Coulot
Tel.: +33 (0)1 44 71 20 40
implanet@newcap.eu
NewCap
Media Relations
Nicolas Merigeau
Tel.: +33 (0)1 44 71 94 98
implanet@newcap.eu